Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

Imiquimod improved skin pigmentation in most patients with xeroderma pigmentosum and may prevent further skin cancer, but some treatments can have side effects.

A woman developed Cushing syndrome and adrenal insufficiency from using fluticasone and ritonavir together.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

A woman's hair loss was likely caused by a cream used for skin treatment and improved after she stopped using it.

A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Imiquimod can cause rare skin side effects, some irreversible, and long-term follow-up is important for users.

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.

Fluridil safely promotes hair growth in men with androgenetic alopecia.

Cladribine has known risks and potential new safety concerns, requiring careful monitoring.

ZD1839 (Iressa) causes skin and hair side effects, treatable with tretinoin cream and minocycline.

Bicalutamide may reduce hair shedding in women but needs longer trials to confirm its effectiveness.

Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.

New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.

Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.

Ritlecitinib was generally well tolerated in children with alopecia areata.

Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.

Pimecrolimus boosts melanin production and movement of skin pigment cells.

Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.

Fluridil safely promotes hair growth in men with androgenetic alopecia.

A woman had a severe skin reaction from the drug imiquimod, used for skin cancer, highlighting the need for awareness of rare but serious side effects.

Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.

Methotrexate is not proven to maintain remission in ulcerative colitis.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.